過繼性細胞療法市場：按類型、應用、最終用戶和地區分類

Adoptive Cell Therapy Market, By Type (CAR-T, TCR-T, NK, TIL), By Application (Lymphoma, Leukemia, Others), By End User (Hospitals, Cancer Treatment Centers), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版日期: 2026年03月06日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026年過繼性細胞療法市場規模為124.5億美元，預計2033年將達224億美元。預計2026年至2033年，該市場將以12.1%的複合年成長率成長。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	124.5億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	12.10%	預計金額（2033 年）	224億美元

過繼性細胞療法（ACT）是一種免疫療法，它將T細胞（一種免疫細胞）輸注給患者，以幫助他們對抗癌症等疾病。過繼性細胞療法包括嵌合體抗原受體（CAR）T細胞、T細胞受體（TCR）T細胞、腫瘤浸潤淋巴細胞（TIL）和自然殺手（NK）細胞。在過繼性細胞療法中，將實驗室大量培養的免疫細胞輸注到患者體內以攻擊癌細胞。在某些情況下，會使用能夠自然辨識黑色素瘤的免疫細胞；而在其他情況下，則會使用經過基因改造、能夠辨識並殺死黑色素瘤細胞的免疫細胞。過繼性細胞療法又稱為T細胞轉移療法或細胞免疫療法。

市場動態

全球過繼性細胞療法市場主要企業正致力於採取產品發布、合作和資金籌措等成長策略，預計這些策略將在預測期內推動市場成長。例如，2021年1月，全球臨床階段生物製藥公司Gracell Biotechnologies Inc.宣布，其FasTCAR負載的BCMA/CD19雙標靶CAR-T細胞療法「GC012F」已獲得美國食品藥物管理局（FDA）授予的孤兒藥資格認定，用於治療多發性固體癌與主要企業Glycostem Therapeutics BV宣布，雙方已達成協議。 Zelluna Immunotherapy 與 Glycostem Therapeutics BV 的這項合作將專注於開發和生產用於治療癌症患者的同種異體 TCR 誘導的 NK 細胞療法 (TCR-NK)。

本報告的主要特點

本報告指出了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本節根據以下參數介紹全球過繼性細胞療法市場中主要企業的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球過繼細胞療法市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過分析全球過繼性細胞療法市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
市佔率分析
公司簡介
- Novartis AG
- Gilead Sciences, Inc.
- Castle Creek Biosciences, Inc.
- Lineage Cell Therapeutics, Inc.
- Transgene SA
- Cellectis
- ImmunityBio, Inc.
- Sorrento Therapeutics
- bluebird bio, Inc.
- Arcellx
- Sana Biotechnology, Inc.
- Biodesix, Inc
- Laurus Labs

第9章

參考
分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI4957

Adoptive Cell Therapy Market is estimated to be valued at USD 12.45 Bn in 2026 and is expected to reach USD 22.4 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 12.45 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	12.10%	2033 Value Projection:	USD 22.4 Bn

Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells (a type of immune cell) are given to a patient to help the body fight diseases, such as cancer. Types of adoptive cell therapy include chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, tumor infiltrating lymphocytes (TILs), and natural killer (NK) cells. Adoptive cell therapy involve use of immune cells that are grown in the lab in large numbers followed by administering them to the body to fight cancer. Sometimes, immune cells that naturally recognize melanoma are used, while other times they are modified to make them recognize and kill the melanoma cells. Adoptive cell therapy is also called T-cell transfer therapy, and cellular immunotherapy.

Market Dynamics

Key players operating in the global adoptive cell therapy market are focusing on adoption of growth strategies such as product launch, collaboration, and fundraise which are expected to drive the market growth during the forecast period. For instance, in January 2021, Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for GC012F, Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma. Moreover, in November 2019, Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment of multiple solid cancers, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company announced that they have entered into a development, license and supply agreement. This collaboration between Zelluna Immunotherapy and Glycostem Therapeutics BV will focus on the development and manufacture of allogeneic TCR guided NK cell therapies (TCR-NK's) for the treatment of patients with cancer

Key features of the study

This report provides an in-depth analysis of the global adoptive cell therapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global adoptive cell therapy market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global adoptive cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global adoptive cell therapy market

Market Segmentation

By Type
- CAR-T
- TCR-T
- NK
- TIL
By Application
- Lymphoma
- Leukemia
- Others
By End User
- Hospitals
- Cancer Treatment Centers
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Key Players
- Novartis AG
- Gilead Sciences, Inc.
- Castle Creek Biosciences, Inc.
- Lineage Cell Therapeutics, Inc.
- Transgene SA
- Cellectis
- ImmunityBio, Inc.
- Sorrento Therapeutics, bluebird bio, Inc.
- Arcellx, Sana Biotechnology, Inc.
- Biodesix, Inc
- Laurus Labs

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Adoptive Cell Therapy Market, By Type, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026- 2033
- Segment Trends
CAR-T
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
TCR-T
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
NK
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
TIL
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

5. Adoptive Cell Therapy Market, By Application, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

6. Adoptive Cell Therapy Market, By End User, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
Cancer Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

7. Adoptive Cell Therapy Market, By Region, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa